Lupin’s investments in Research and Development (R&D) have helped us gain a leadership position in differentiated product introductions and become a formidable player in the generics space.
At Lupin, we are embracing advanced technologies, scientific breakthroughs and partnerships that enable us to advance research and development towards building a diversified portfolio and gain a leadership position in important new product introductions. Our Research & Development helps build a solid foundation as we progress to become a Complex Generics, Biosimilars and Specialty front runner.
Lupin has a solid team of 1,700 scientists and technologists employed at state-of-the-art facilities across the world. We are well on track to emerge as an innovation-led transnational pharmaceutical organisation providing affordable healthcare solutions with uncompromising quality. Within Europe, Nanomi, a Lupin business, leads the field in nanoparticle manufacture and complex injectable development.
Lupin’s research scientists have a proven track record of delivering high-quality technology-intensive products, Active Pharmaceutical Ingredients (APIs), formulations and newer dispensation forms.
UK-LUP-2208-00003 DOP: September 2022